Impact of c-peptide preservation on metabolic and clinical outcomes in the diabetes control and complications trial

Diabetes

Volumn 63, Issue 2, 2014, Pages 739-748

  Lachin, John M ^a   McGee, Paula ^a   Palmer, Jerry P ^b,c  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Puget Sound Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C PEPTIDE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE DURATION; DRUG DOSE REDUCTION; EXCRETION; FEMALE; HUMAN; HYPOGLYCEMIA; INTENSIVE CARE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETINOPATHY; RISK FACTOR; STIMULATION;

ADULT; C-PEPTIDE; DIABETES MELLITUS; DIABETIC RETINOPATHY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; TIME FACTORS; YOUNG ADULT;

EID: 84893119634     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0881     Document Type: Article

References (11)

1. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001 [published correction appears in Diabetes 2004;53:1934]. Diabetes 2004;53:250-264
2. Palmer JP. C-peptide in the natural history of type 1 diabetes. Diabetes Metab Res Rev 2009;25:325-328
3. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987;65:30-36
4. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual b-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann Intern Med 1998;128:517-523
5. Steffes MW, Sibley S, Jackson M, Thomas W. b-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
7. The DCCT Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995;38:869-880
8. Cleveland WS, Grosse E. Computational methods for local regression. Stat Comput 1991;1:47-62
9. Demidenko E. Mixed Models: Theory and Applications. Hoboken, John Wiley & Sons, 2004
10. Lachin JM. Biostatistical Methods: The Assessment of Relative Risks. 2nd ed. Hoboken, John Wiley & Sons, 2011
11. Fukuda M, Tanaka A, Tahara Y, et al. Correlation between minimal secretory capacity of pancreatic b-cells and stability of diabetic control. Diabetes 1988;37:81-88